focus -WSS

focus

author：explore 2025-09-29 23:04:29 - browse：1

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Heart attack and stroke risk calculators need revising
Next article： Fauci’s Covid grilling leads GOP to weigh foreign research rules

knowledge

explore

WSS

IVF, abortion rights issues kick off Biden’s State of the Union

How to bring more disabled researchers into academia

Amylyx ALS drug failure raises questions and concerns

Caregivers of transplant patients call for more support, training

The SUPPORT Act is critical to fighting the opioid crisis

Change Healthcare payments predicted restored March 15

leisure time

focus

leisure time

Peter Hotez and the public health issue of online harassment

Amylyx ALS drug fails large clinical trial

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Continuity nursing helped my family in our darkest PICU moments

RSV shot was 90% effective at preventing hospitalizations in kids

Psychedelics group wrestles with new pharma identity

New menopause drug shows promise in relief for hot flashes

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

entertainment

IVF, abortion rights issues kick off Biden’s State of the Union

Doulas covered by Medicaid under New York's new plan

The SUPPORT Act is critical to fighting the opioid crisis

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

New menopause drug shows promise in relief for hot flashes

JPM 2024: Nvidia claims we're in biological revolution. Are we?

knowledge

explore

Wikipedia

leisure time